重组人促红细胞生成素治疗肿瘤化疗相关性贫血的临床观察  

Clinical observation of recombinant human erythropoietin on chemotherapy-related anemia

作　　者：宋晓鹏[1] 魏红梅[1] 张立成[1] 李萌[1] 任守雷[1] 张蕾[1] 

机构地区：[1]中国人民解放军第88医院肿瘤中心,山东泰安271000

出　　处：《泰山医学院学报》2012年第10期716-718,共3页Journal of Taishan Medical College

摘　　要：目的观察重组人促红细胞生成素(rhEPO)治疗肿瘤化疗相关性贫血的疗效和安全性。方法进展期恶性合并化疗相关性贫血的患者32例,与化疗同步予以皮下注射rhEPO 100 u/(kg.次),每周3次,连用8周,比较治疗前后血红蛋白(Hb)、红细胞比容(HCT)、网织红细胞和生活质量的变化。结果 32例患者经rhEPO治疗后8周,与治疗前相比,血红蛋白、红细胞、血细胞比容和网织红细胞均有明显改善(P<0.05),其中Hb上升≥20 g/L者17例,有效率为53.1%;与治疗前比较,体质状态评分(KPS评分)均有不同程度改善。结论化疗联合rhEPO既能明显提高肿瘤患者的血红蛋白水平,可预防并治疗化疗相关性贫血的发生,又能改善其生活质量,安全可靠。Objective ： To evaluate the effects and safety of recombinant human erythropoietin （rhEPO） for patients of chemotherapy - related anemia. Methods ： A total of 32 advanced cancer patients received rhEPO at a dose of 100 u/kg each time subcutaneously, and three times a week for 8 weeks in combination with chemotherapy. The levels of Hb, HCT, RET and the quality of life were monitored before and after rhEPO treatment. Results： The levels of Hb, HCT, RET and KPS were improved at 8 weeks after treatment. In 19 patients, Hb increased to 20 g/L. Conclusion： The rhEPO is safe and effective in maintaining Hb levels and QOL in advanced cancer patients in combination with chemotherapy.

关 键 词：肿瘤相关性贫血 重组人促红细胞生成素 输血治疗 生活质量 

分 类 号：R730.6[医药卫生—肿瘤]